Your session is about to expire
← Back to Search
TVB-2640 for Non-alcoholic Fatty Liver Disease
Study Summary
This trial will study whether TVB-2640 is safe and effective in people with non-alcoholic steatohepatitis (NASH). Participants will be given the drug or a placebo pill to take once a day for 52 weeks.
- Non-alcoholic Fatty Liver Disease (NAFLD)
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 trial • 25 Patients • NCT03032484Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are currently using drugs or alcohol in a harmful or excessive way.You must be willing and able to participate in the study and provide written informed consent.You are not of childbearing potential, you are not pregnant, you are not breastfeeding, you are not planning to become pregnant, and you are not using birth control.You have been drinking a lot of alcohol for more than 3 months in a row within the past year, as determined by the doctor in charge.You must have a liver stiffness measurement ≥8.
- Group 1: TVB-2640 50 mg
- Group 2: Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many sites are currently administering this trial?
"Impact Research Institute in Waco, Texas, Jubilee Clinical Research Inc. in Las Vegas, Nevada and University of Gastroenterology in Providence Rhode island are among the 100 sites that form part of this clinical trial's infrastructure."
Are there any opportunities to join this research initiative at present?
"According to clinicaltrials.gov, this experiment is no longer accepting volunteers at this time as it was last modified on September 30th 2022. Fortunately, there are 370 other medical trials currently recruiting participants."
Does TVB-2640 pose health risks to those using it therapeutically?
"Data regarding TVB-2640's efficacy was limited, thus our team assigned a score of 2 reflecting the relative lack of clinical data supporting its safety."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
Share this study with friends
Copy Link
Messenger